The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1525
ISSUE1525
July 17, 2017
Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea
July 17, 2017 (Issue: 1525)
The FDA has approved telotristat ethyl (Xermelo –
Lexicon), a tryptophan hydroxylase inhibitor, for
use in combination with a somatostatin analog
(SSA) for treatment of carcinoid syndrome diarrhea
inadequately controlled with SSA therapy...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.